Trials / Completed
CompletedNCT03334084
A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects
A Randomized, Open-label, Parallel Group Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety and Tolerability of a Subcutaneous Formulation With an Intravenous Formulation of ARGX-113 in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- argenx · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The study is a Randomized, Open-label, Parallel Group Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety and Tolerability of a Subcutaneous Formulation With an Intravenous Formulation of ARGX-113 in Healthy Male Subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARGX-113 | intravenous or subcutaneous administration |
Timeline
- Start date
- 2017-10-11
- Primary completion
- 2018-09-19
- Completion
- 2018-09-19
- First posted
- 2017-11-07
- Last updated
- 2020-08-31
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT03334084. Inclusion in this directory is not an endorsement.